Published in the Journal of Neurology, this is an updated interim report from the ongoing Strategic Targeting of Registries and International Database of Excellence (STRIDE) international, multicenter registry of real-world ataluren use in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
Publication: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis
MED-ALL-CORP-2200029 | September 2023
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.